ZDA
RVMD icon

Zweig-DiMenna Associates’s Revolution Medicines RVMD Stock Holding History

Zweig-DiMenna Associates’s Portfolio RVMD Stock Details RVMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$22.5M Buy
120,200
+111,913
+1,350% +$16.3M 2.04% 15
2026
Q1 		$806K Sell
8,287
-96,313
-92% -$9.73M 0.11% 58
2025
Q4 		$8.33M Buy
+104,600
New +$6.86M 0.52% 63

Other funds holding RVMD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Zweig-DiMenna Associates's RVMD Position: Q2 2026 in Review

Zweig-DiMenna Associates increased its Revolution Medicines (RVMD) stake by 1,350% in Q2 2026, buying an estimated $16.3M and bringing the position to 120,200 shares worth $22.5M. The position accounts for 2.04% of the portfolio, ranked #15.

Zweig-DiMenna Associates first reported a position in RVMD in Q4 2025 and has held it in 3 quarters since. 690 funds tracked by Wall St. Rank hold RVMD as of Q2 2026.

  • Zweig-DiMenna Associates held 120,200 shares of Revolution Medicines worth $22.5M as of Q2 2026.
  • Zweig-DiMenna Associates bought 111,913 Revolution Medicines shares in Q2 2026, an estimated $16.3M.
  • Revolution Medicines made up 2.04% of Zweig-DiMenna Associates's portfolio in Q2 2026, its #15 holding.
  • Zweig-DiMenna Associates first reported a position in Revolution Medicines in Q4 2025 and has held it in 3 quarters since.
  • 690 funds tracked by Wall St. Rank held Revolution Medicines as of Q2 2026.

Based on Zweig-DiMenna Associates's 13F filing for Q2 2026, filed 13 Aug 2026.